Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 2009-2013

  Chen, Fanghong ^a   Langenstroer, Peter ^a   Zhang, Guangjian ^a   Iwamoto, Yoshiki ^a   See, William A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Androgens; Bladder; Carcinoma, transitional cell; Interleukin 6; Mycobacterium bovis

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BCG VACCINE; BICALUTAMIDE; CELL SURFACE RECEPTOR; HYDROXYFLUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA;

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

EID: 0141885265     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000092238.15685.10     Document Type: Article

References (21)

1. Malkowicz, S. B.: Intravesical therapy for superficial bladder cancer. Semin Urol Oncol, 18: 280, 2000
2. Herr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., Jr. et al: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol, 13: 1404, 1995
3. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 163: 1124, 2000
4. Cookson, M. S., Herr, H. W., Zhang, Z. F., Soloway, S., Sogani, P. C. and Fair, W. R.: The treated natural history of high-risk superficial bladder cancer: 15-year outcome. J Urol, 158: 62, 1997
5. Sosnowski, J. T.: Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer. Compr Ther, 20: 695, 1994
6. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. and Ratliff, T. L.: Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest, 85: 62, 1990
7. Ratliff, T. L., Palmer, J. O., McGarr, J. A. and Brown, E. J.: Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res, 47: 1762, 1987
8. Aslanzadeh, J., Brown, E. J., Quillin, S. P., Ritchey, J. K. and Ratliff, T. L.: Characterization of soluble fibronectin binding to Bacille Calmette-Guerin. J Gen Microbiol, 135: 2735, 1989
9. Zhang, G. J., Crist, S. A., McKerrow, A. K., Xu, Y., Ladehoff, D. C. and See, W. A.: Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the α5 β1 fibronectin receptor. J Urol, 163: 1553, 2000
10. Chen, F. H., Crist, S. A., Zhang, G.-J., Iwamoto, Y. and See, W. A.: Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guerin through nuclear factor-κb and AP-1 via an immediate early pathway. J Urol, 168: 786, 2002
11. Keller, E. T., Chang, C. and Ershler, W. B.: Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem, 271: 26267, 1996
12. Hofbauer, L. C., Ten, R. M. and Khosla, S.: The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Min Res, 14: 1330, 1999
13. Blackledge, G. R., Cockshott, I. D. and Furr, B. J.: Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur Urol, suppl., 31: 30, 1997
14. Labrie, F.: Mechanism of action and pure antiandrogenic properties of flutamide. Cancer, 72: 3816, 1993
15. Sander, B., Damm, O., Gustafsson, B., Andersson, U. and Håkansson, L.: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin. J Urol, 156: 536, 1996
16. de Reijke, T. M., de Boer, E. C., Kurth, K. H. and Schamhart, D. H. J.: Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol, 155: 477, 1996
17. Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S. et al: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol, 99: 369, 1995
18. Zhuang, Y. H., Blauer, M., Tammela, T. and Tuohimaa, P.: Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology, 30: 556, 1997
19. Laor, E., Schiffman, Z. J., Braunstein, J. D., Reid, R. E., Tolia, B. M., Koss, L. G. et al: Androgen receptors in bladder tumors. Urology, 25: 161, 1985
20. Biswas, D. K., Dai, S. C., Cruz, A., Weiser, B., Graner, E. and Pardee, A. B.: The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA, 98: 10386, 2001
21. Furr, B. J. and Jordan, V. C.: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther, 25: 127, 1984